Ipsen initiates a share buyback program to cover its new free share allocation plan
Ipsen initiates a share buyback program to cover its new free share allocation plan
Paris (France), 18 June 2019 – Ipsen (Euronext: IPN; ADR: IPSEY), announces today that it has appointed an investment services provider to purchase 150,000 Ipsen SA shares, or about 0.18% of the share capital, over a period of maximum 2 months. The shares purchased under this agreement will be mainly allocated to cover its new free employee share allocation plan.
This program is made pursuant to the authorization granted by the Combined Shareholders’ Meeting held on 28 May 2019.
Ipsen initiates a share buyback program to cover its new free share allocation plan
Paris (France), 18 June 2019 – Ipsen (Euronext: IPN; ADR: IPSEY), announces today that it has appointed an investment services provider to purchase 150,000 Ipsen SA shares, or about 0.18% of the share capital, over a period of maximum 2 months. The shares purchased under this agreement will be mainly allocated to cover its new free employee share allocation plan.
This program is made pursuant to the authorization granted by the Combined Shareholders’ Meeting held on 28 May 2019.
Related Press Releases

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Half-year statement of IPSEN liquidity agreement – 2024 06 30

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
